SZLSF (StageZero Life Sciences) Long-Term Debt: $0.87 Mil (As of Sep. 2024)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.01
View Full Analysis

What is StageZero Life Sciences Long-Term Debt?

StageZero Life Sciences SZLSF 10 Long-Term Debt is $0.87 Mil as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.87 Mil.

StageZero Life Sciences's quarterly Long-Term Debt increased from Mar. 2024 ($0.81 Mil) to Jun. 2024 ($0.84 Mil) and increased from Jun. 2024 ($0.84 Mil) to Sep. 2024 ($0.87 Mil).

StageZero Life Sciences's annual Long-Term Debt increased from Dec. 2020 ($0.58 Mil) to Dec. 2021 ($0.58 Mil) but then declined from Dec. 2021 ($0.58 Mil) to Dec. 2022 ($0.58 Mil).

StageZero Life Sciences  (OTCPK:SZLSF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

StageZero Life Sciences Long-Term Debt Related Terms

StageZero Life Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Long-Term Debt Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.95 0.57 0.58 0.58 0.58

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.74 0.81 0.84 0.87
SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.87 Mil mean?
StageZero Life Sciences (SZLSF) has a Long-Term Debt of $0.87 Mil as of Sep. 2024.
Is StageZero Life Sciences' Long-Term Debt too high?
StageZero Life Sciences' current Long-Term Debt is $0.87 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Long-Term Debt compare to IDTA and TTOO?
StageZero Life Sciences' Long-Term Debt of $0.87 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. StageZero Life Sciences's current Long-Term Debt is $0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current Long-Term Debt of $0.87 Mil. The current Long-Term Debt is $0.87 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Long-Term Debt is $0.87 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price